NasdaqCM - Nasdaq Real Time Price USD

Daxor Corporation (DXR)

7.53

-0.21

(-2.71%)

At close: May 2 at 4:00:00 PM EDT

7.77

+0.24

+(3.19%)

After hours: May 2 at 4:05:12 PM EDT

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Daxor Brings Advanced Blood Volume Analysis Solutions to Elite Heart and Lung Transplantation Forum Oak Ridge, TN, April 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, will attend the 45th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions. This premier event gathers approximately 3,500 international specialists in advanced heart and lung disease treatment for four days o

GlobeNewswire 11 days ago

DXR
-2.71%
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

WellStar Health System to Highlight New BVA-Driven Strategy That Significantly Reduces Kidney Injury Following LVAD Implantation Oak Ridge, TN, April 17, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’25 Conference being held at the Renaissance Orlando at SeaWorld in Orlando, FL from April 24-26, 2025. The Cardiovascular Transforum conference unites card

GlobeNewswire 16 days ago

DXR
-2.71%
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Precise Volume Measurement Prior to Discharge Identifies Mortality Risk Oak Ridge, TN, April 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced compelling new data presented at the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. Research from The Minneapolis Heart Institute Foundation® and Allina Health Minneapolis Heart Institute® demonstrated tha

GlobeNewswire 18 days ago

DXR
-2.71%
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer

Advanced BVA System Designed for Faster, Simpler Bedside Testing Oak Ridge, TN, April 10, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, announces today the submission of its next-generation blood volume analyzer - Daxor BVA - to the Food and Drug Administration (FDA.), advancing its mission to optimize healthcare through precise fluid management. The new Daxor BVA device represents a significant leap forward in diagnostic technology, o

GlobeNewswire 23 days ago

DXR
-2.71%
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo

BVA and Pressure Session Attracted 400+ Clinicians; Duke University Showcased Valuable New BVA Findings in Dedicated Poster Presentation Oak Ridge, TN, April 02, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces excellent visibility of Daxor’s technology at the premier global cardiology conference, the American College of Cardiology (ACC) 74th Annual Scientific Session and Expo held in Chicago from March 29-31st. New dat

GlobeNewswire last month

DXR
-2.71%
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Regional Medical Leaders Embrace Daxor’s ezBVA Lab Service Oak Ridge, TN, March 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into three regional healthcare facilities across the U.S. These facilities will use Daxor's Tennessee-based ezBVA Lab, a CLIA-certified facility equipped with state-of-the-art technology. The ezBVA Lab delivers comprehensive blood volume analysis (BVA)

GlobeNewswire last month

DXR
-2.71%
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period

GlobeNewswire last month

DXR
-2.71%
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will host an investor conference call on Thursday, March 6, 2025, at 4:30 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will review financial results and provide an update on corporate developments. After Management’s presentation, there will be an opportunity for Q&A. Investors are encouraged to submit questions in a

GlobeNewswire last month

DXR
-2.71%
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 04, 2025 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Behind every overnight success is a decade of relentless work that nobody saw." — Anonymous As we forge ahead into this pivotal year, Daxor remains laser-focus

GlobeNewswire last month

DXR
-2.71%
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2023 versus $7.08 for the comparable period

GlobeNewswire last month

DXR
-2.71%
Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care Oak Ridge, TN, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor, the global leader in blood volume measurement technology, today announces a significant expansion into a leading Midwest healthcare facility. This 735-bed medical campus will integrate Daxor’s blood volume analysis (BVA) testing into its outpatient care, enhancing precision in fluid management and patie

GlobeNewswire 2 months ago

DXR
-2.71%
Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Leading Academic Health System Adopts Daxor’s Innovative Blood Volume Measurement Capabilities at Two Key Facilities Oak Ridge, TN, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of its blood volume analysis (BVA) at two major hospitals within New Jersey’s largest academic health care system. Based on current market momentum and expanding pipeline of opportunities, the Company expects to m

GlobeNewswire 2 months ago

DXR
-2.71%
Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

Two Groundbreaking Studies on Fluid Management: Pulmonary Artery Pressure Monitoring Falls Short, New Diuretic Insights Emerge Oak Ridge, TN, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces groundbreaking new studies from Duke University Medical Center and Yale School of Medicine, presented at the Technology and Heart Failure Therapeutics Conference (THT). Held from February 11-13, 2025, at the Omni Boston Hot

GlobeNewswire 2 months ago

DXR
-2.71%
Daxor to Exhibit at World's Largest Critical Care Conference

Daxor’s Blood Volume Analysis (BVA) Technology Takes Center Stage at SCCM 2025 Oak Ridge, TN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society for Critical Care Medicine (SCCM) 2025 Critical Care Congress at the Orange County Convention Center in Orlando, FL from February 23 through February 25, 2025. The Company will be exhibiting at Booth #532. "With 5.7 million annu

GlobeNewswire 2 months ago

DXR
-2.71%
Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart Failure Treatment Oak Ridge, TN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a groundbreaking case series published in JACC: Case Reports has identified a distinct phenotype in heart failure patients characterized by expanded blood volume overload and elevated re

GlobeNewswire 2 months ago

DXR
-2.71%
New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care

Research Published in the Prestigious Journal of Cardiac Failure From Three Institutions Oak Ridge, TN, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor’s Blood Volume Analysis (BVA). The study demonstrates how BVA outperforms standard hemody

GlobeNewswire 2 months ago

DXR
-2.71%
Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

Healthcare Providers Embrace Blood Volume Analysis (BVA) in Nephrology and Heart Failure Outpatient Care Oak Ridge, TN, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces expansion of its ezBVA Lab service to two new health systems. Daxor's ezBVA Lab provides cost-effective blood volume analysis, offering comprehensive sample processing with minimal initial investment. The service has broad reimbursement co

GlobeNewswire 4 months ago

DXR
-2.71%
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Elite Cardiovascular Leaders Unite: Driving Innovation Through Shared Excellence Oak Ridge, TN, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall’24 Conference being held at the Gaylord Rockies Resort & Convention Center in Aurora, CO, October 17-19, 2024. The CV Transforum is the leading conference for cardiovascular organizational

GlobeNewswire 6 months ago

DXR
-2.71%
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oak Ridge, TN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Maxim Director of Research and Senior Healthcare Analyst Anthony Vendetti. The summit is being held from October 15 – 17, 2024. Event:Fireside Chat at 2024 Maxim Healthcare Virtual SummitDate:Tuesday, October 15, 2024T

GlobeNewswire 6 months ago

DXR
-2.71%
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces a strategic update to its regulatory approach for its novel diagnostic blood volume analyzer platform. Following productive discussions with the U.S. Food and Drug Administration (FDA), the company has decided to withdraw its current dual 510(k)/CLIA-waiver application and

GlobeNewswire 7 months ago

DXR
-2.71%

Performance Overview

Return	DXR	S&P 500 (^GSPC)
YTD	-2.08%	-3.31%
1-Year	-23.79%	+12.29%
3-Year	-36.24%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daxor Corporation (DXR)

Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025

New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer

Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo

Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023

Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Daxor Corporation Announces New Data on Blood Volume Analysis from Duke and Yale Universities Presented at THT 2025

Daxor to Exhibit at World's Largest Critical Care Conference

Daxor's Blood Volume Analysis Uncovers Hidden Heart Failure Subtype in Nearly 1 in 5 Patients, Enabling Targeted Treatment

New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care

Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum

DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24

Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

Performance Overview